| Source: |
Escherichia coli |
| Molecular Weight: |
Approximately 15.6 kDa, a single non-glycosylated polypeptide chain containing 136 amino acids. |
| AA Sequence: |
SSSFDKGKYK KGDDASYFEP TGPYLMVNVT GVDGKRNELL SPRYVEFPIK PGTTLTKEKI EYYVEWALDA TAYKEFRVVE LDPSAKIEVT YYDKNKKKEE TKSFPITEKG FVVPDLSEHI KNPGFNLITK VVIEKK |
| Purity: |
> 97% by SDS-PAGE and HPLC analyses. |
| Biological Activity: |
Fully biologically active when compared to standard. The specific activity determined by fibrining lysis in agarose plate is 5.0 × 104 IU/mg. |
| Physical Appearance: |
Sterile filtered white lyophilized (freeze-dried) powder. |
| Formulation: |
Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH7.4. |
| Endotoxin: |
Less than 1 EU/µg of rSAK as determined by LAL method. |
| Reconstitution: |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-0.5 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions. |
| Stability & Storage: |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution. |
| Synonyms: |
Sak42D |
| Background: |
Staphylokinase (SAK) is an enzyme composed of amino acids, produced by various streptococcal species. This enzyme, weighing 16kDa, is a powerful activator of plasminogen. Plasminogen is converted into plasmin by SAK, which in turn breaks down fibrin, a primary component of blood clots. SAK forms a 1:1 complex with plasmin, fostering a positive feedback loop that generates additional complexes.
Recent research has highlighted the thrombolytic potential of recombinant SAK. It demonstrates efficacy in achieving early perfusion during myocardial infarction and in dissolving clots rich in platelets. These findings underscore its significant clinical utility as a thrombolytic agent, suggesting it could be further developed into a potent clot-dissolving treatment. |
